SCHEMBL4979174

SCHEMBL4979174

C=CCc1cc(C(=O)OCC)ccc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.57
PTPN1 P18031 4/20 0.54
MAPT P10636 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GAA P10253 1/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.47
LMNA P02545 2/20 0.47
ALOX5 P09917 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542900 0.87 PTPN1 (0.57) PTPN1MAPTMEN1KMT2ANPC1
SCHEMBL4982250 0.84 PTPN1 (0.60) PTPN1MAPTMEN1KMT2ARAB9A
SCHEMBL1515872 0.83 CA12 (0.62) HSD17B2PTPN1ALDH1A1KDM4ECA12
SCHEMBL29022766 0.83 KDM4E (0.51) HSD17B2MAPTMEN1KMT2ARAB9A
SCHEMBL4981784 0.82 ALDH1A1 (0.61) PTPN1MEN1KMT2AALDH1A1GAA
SCHEMBL1351357 0.81 HSD17B2 (0.61) HSD17B2MAPTMEN1KMT2ANPC1
SCHEMBL5344735 0.81 HSD17B2 (0.61) HSD17B2MAPTMEN1KMT2ANPC1
SCHEMBL8772571 0.80 SMN1; SMN2 (0.45) HSD17B2PTPN1MEN1KMT2ANPC1
SCHEMBL9733519 0.80 PTPN1 (0.56) PTPN1MAPTMEN1KMT2AKDM4E
SCHEMBL4979459 0.80 HSP90AA1 (0.58) PTPN1MEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives TPH1, HTR1D, HTR1B HSD17B2 1317/4885PTPN1 3204/4885MAPT 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.